TG Therapeutics, Inc. (TGTX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

TG Therapeutics, Inc.

Catalyst Pharmaceuticals, Inc.

IDEAYA Biosciences, Inc.

Springworks Therapeutics, Inc.

Taro Pharmaceutical Industries Ltd.

Ironwood Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Pacira Biosciences, Inc.

CureVac NV

Crinetics Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

Why is TG Therapeutics, Inc. ?

With a growth in Operating Profit of 60.71%, the company declared Outstanding results in Sep 25

ROCE(HY) Highest at 111.96%
NET SALES(Q) Highest at USD 161.71 MM
INVENTORY TURNOVER RATIO(HY) Highest at 0.68 times

With ROE of 73.74%, it has a fair valuation with a 7.57 Price to Book Value

Over the past year, while the stock has generated a return of -24.60%, its profits have risen by 3248.9%

High Institutional Holdings at 75.93%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to TG Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is TG Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

TG Therapeutics, Inc.

-23.65%

1.93

46.10%

S&P 500

14.9%

0.77

19.29%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

251.00%

EBIT Growth (5y)

19.69%

EBIT to Interest (avg)

-23.08

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.13

Sales to Capital Employed (avg)

0.77

Tax Ratio

6.21%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

75.93%

ROCE (avg)

24.02%

ROE (avg)

8.40%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

7.57

EV to EBIT

45.83

EV to EBITDA

45.72

EV to Capital Employed

6.52

EV to Sales

8.86

PEG Ratio

Dividend Yield

ROCE (Latest)

14.23%

ROE (Latest)

73.74%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

33What is working for the Company

ROCE(HY)

Highest at 111.96%

NET SALES(Q)

Highest at USD 161.71 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 0.68 times

PRE-TAX PROFIT(Q)

At USD 25.49 MM has Grown at 52.24%

NET PROFIT(Q)

Highest at USD 390.47 MM

EPS(Q)

Highest at USD 2.43

-8What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -70.07 MM

DEBT-EQUITY RATIO (HY)

Highest at 20.11 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.79 times

RAW MATERIAL COST(Y)

Grown by 7.06% (YoY

Here's what is working for TG Therapeutics, Inc.

Net Profit

At USD 390.47 MM has Grown at 2,450.22%

over average net sales of the previous four periods of USD 15.31 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Sales

Highest at USD 161.71 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (USD MM)

Net Sales

At USD 161.71 MM has Grown at 42.45%

over average net sales of the previous four periods of USD 113.52 MM

MOJO Watch

Near term sales trend is very positive

Net Sales (USD MM)

Pre-Tax Profit

At USD 25.49 MM has Grown at 52.24%

over average net sales of the previous four periods of USD 16.74 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD 390.47 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD 2.43

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Inventory Turnover Ratio

Highest at 0.68 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for TG Therapeutics, Inc.

Debt-Equity Ratio

Highest at 20.11 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 2.79 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Operating Cash Flow

Lowest at USD -70.07 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Raw Material Cost

Grown by 7.06% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales